Core Biogenesis fights against cancer and neurodegenerative diseases
Core Biogenesis has raised €20M across 2 funding rounds from 5 investors, most recently a Series A round in Jul 2022. Based in Strasbourg, France; active in Healthtech. Data as of 6 Aug 2026.
Timing: overdue vs cohort gap · momentum flat. Funding-only estimates, not predictions and not investment advice — see signals.
| Date | Stage |
|---|
| Amount |
|---|
| Investors |
|---|
| 2022-07-29 | Series A | €10M | Blue Horizon Ventures,Thia Ventures,XAnge | View deal → |
| 2022-03-29 | Other | €10M | Angel Investors,Blue Horizon Ventures,Entrepreneur First,Thia Ventures,XAnge | View deal → |
